search
Back to results

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

Primary Purpose

Lymphoma, Non-Hodgkin Lymphoma, B-Cell

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
BAFF CAR-T
Sponsored by
Luminary Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lymphoma, Non-Hodgkin Lymphoma, B-Cell focused on measuring non-Hodgkin lymphoma.

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Subjects must have histologically confirmed non-Hodgkin lymphoma relapsed after 2 or more lines of therapy or disease refractory to chemotherapy (defined as progressive disease or stable disease lasting ≤6 months, as best response to most recent chemotherapy regimen; or disease progression or recurrence ≤12 months after prior autologous stem cell transplantation (ASCT).
  2. No evidence of central nervous system (CNS) lymphoma.
  3. Male or female > 18 years of age.
  4. Eastern Cooperative Oncology Group Performance status ≤ 2.
  5. At least one measurable lesion.
  6. >2 weeks since prior radiation therapy or systemic therapy at the time of leukapheresis.
  7. Total bilirubin ≤ 1.5 mg/dL (except in patients with Gilbert's syndrome).
  8. Aspartate aminotransferase/alanine transferase ≤ 2.5 X institutional upper limit of normal.
  9. Serum creatinine < 1.5 mg/dL.
  10. Cardiac ejection fraction of >50%, and no evidence of pericardial effusion, as determined by an echocardiogram.
  11. Adequate pulmonary function as defined as pulse oximetry ≥ 92% on room air.
  12. Subjects (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document.
  13. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 90 days after the BAFF CAR-T cell infusion.
  14. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.

Exclusion Criteria:

  1. ASCT within 6 weeks of informed consent.
  2. History of allogeneic hematopoietic stem cell transplantation.
  3. Active graft-versus-host disease.
  4. Active central nervous system or meningeal involvement by lymphoma or leukemia.
  5. Active malignancy, other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast).
  6. Less than 28 days elapsed between prior treatment with investigational agent(s) and the day of lymphocyte collection.
  7. New York Heart Association class IV congestive heart failure.
  8. Cardiovascular disorders including unstable angina pectoris, clinically significant cardiac arrhythmias, myocardial infarction or stroke (including transient ischemic attack, or other ischemic event) within 6 months prior to registration.
  9. Active infection requiring intravenous systemic treatment.
  10. HIV seropositivity.
  11. Pregnant or breastfeeding women.
  12. Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy.
  13. Serologic status reflecting active hepatitis B or C infection.
  14. Patients with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.
  15. Subjects with uncontrolled intercurrent illness.
  16. Known additional malignancies which require systemic treatment.
  17. History of autoimmune disease with requirement of immunosuppressive medications (other than low dose steroids) within 6 months.

Sites / Locations

  • University Hospitals Seidman Cancer Center
  • Taussig Cancer Institute | Cleveland ClinicRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

LMY-920 dose escalation

Arm Description

Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.

Outcomes

Primary Outcome Measures

To determine recommended phase II dose of human LMY-920.
Maximum tolerated dose.

Secondary Outcome Measures

To establish toxicity profile for the infusion of LMY-920.
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. All adverse events during study will be collected, categorized, and graded. Attribution of relatedness to the investigational agent will be assigned.
To determine the objective response rate .
Response rate.
To determine the complete response rate.
Response rate.
To determine the duration of response.
Duration of response.
To determine the progression-free survival.
Progression-free survival.
To determine the overall survival.
Overall survival.
To determine incidence of adverse events.
Incidence of adverse events.
To determine incidence of anti- LMY-920 antibodies.
Incidence of anti- LMY-920 antibodies.

Full Information

First Posted
March 24, 2022
Last Updated
January 11, 2023
Sponsor
Luminary Therapeutics
Collaborators
Case Comprehensive Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05312801
Brief Title
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Official Title
LMY-920 for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 23, 2023 (Anticipated)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
September 2, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Luminary Therapeutics
Collaborators
Case Comprehensive Cancer Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.
Detailed Description
LMY-920 is an autologous CAR-T cell therapy consisting of autologous cluster of differentiation 4 (CD4) positive and cluster of differentiation 8 (CD8) positive human T cells that are genetically engineered using the non-viral transposon system to express the BAFF-ligand CAR-T that target BAFF receptor family members to eliminate malignant B cells. BAFF receptor family includes B-cell activating factor receptor (BR3), B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). These receptors are present on non-Hodgkin lymphoma. The goal of LMY-920-001 phase 1 study is to find recommended phase 2 dose of LMY-920 for treatment of patients with relapsed or refractory non-Hodgkin lymphoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lymphoma, Non-Hodgkin Lymphoma, B-Cell
Keywords
non-Hodgkin lymphoma.

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Open label, dose escalation study. Dose Levels 1 x 10 million BAFF+ CAR cells/kg 2 x 10 million BAFF+ CAR cells/kg 4 x 10 million BAFF+ CAR cells/kg 8 x 10 million BAFF+ CAR cells/kg
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LMY-920 dose escalation
Arm Type
Experimental
Arm Description
Open label, dose escalation study with up to four dose levels of LMY-920. The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design.
Intervention Type
Drug
Intervention Name(s)
BAFF CAR-T
Other Intervention Name(s)
LMY-920
Intervention Description
Autologous CAR-T cell therapy expressing the BAFF-ligand.
Primary Outcome Measure Information:
Title
To determine recommended phase II dose of human LMY-920.
Description
Maximum tolerated dose.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
To establish toxicity profile for the infusion of LMY-920.
Description
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. All adverse events during study will be collected, categorized, and graded. Attribution of relatedness to the investigational agent will be assigned.
Time Frame
24 months
Title
To determine the objective response rate .
Description
Response rate.
Time Frame
24 months
Title
To determine the complete response rate.
Description
Response rate.
Time Frame
24 months
Title
To determine the duration of response.
Description
Duration of response.
Time Frame
24 months
Title
To determine the progression-free survival.
Description
Progression-free survival.
Time Frame
24 months
Title
To determine the overall survival.
Description
Overall survival.
Time Frame
24 months
Title
To determine incidence of adverse events.
Description
Incidence of adverse events.
Time Frame
24 months
Title
To determine incidence of anti- LMY-920 antibodies.
Description
Incidence of anti- LMY-920 antibodies.
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects must have histologically confirmed non-Hodgkin lymphoma relapsed after 2 or more lines of therapy or disease refractory to chemotherapy (defined as progressive disease or stable disease lasting ≤6 months, as best response to most recent chemotherapy regimen; or disease progression or recurrence ≤12 months after prior autologous stem cell transplantation (ASCT). No evidence of central nervous system (CNS) lymphoma. Male or female > 18 years of age. Eastern Cooperative Oncology Group Performance status ≤ 2. At least one measurable lesion. >2 weeks since prior radiation therapy or systemic therapy at the time of leukapheresis. Total bilirubin ≤ 1.5 mg/dL (except in patients with Gilbert's syndrome). Aspartate aminotransferase/alanine transferase ≤ 2.5 X institutional upper limit of normal. Serum creatinine < 1.5 mg/dL. Cardiac ejection fraction of >50%, and no evidence of pericardial effusion, as determined by an echocardiogram. Adequate pulmonary function as defined as pulse oximetry ≥ 92% on room air. Subjects (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 90 days after the BAFF CAR-T cell infusion. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm. Exclusion Criteria: ASCT within 6 weeks of informed consent. History of allogeneic hematopoietic stem cell transplantation. Active graft-versus-host disease. Active central nervous system or meningeal involvement by lymphoma or leukemia. Active malignancy, other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast). Less than 28 days elapsed between prior treatment with investigational agent(s) and the day of lymphocyte collection. New York Heart Association class IV congestive heart failure. Cardiovascular disorders including unstable angina pectoris, clinically significant cardiac arrhythmias, myocardial infarction or stroke (including transient ischemic attack, or other ischemic event) within 6 months prior to registration. Active infection requiring intravenous systemic treatment. HIV seropositivity. Pregnant or breastfeeding women. Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy. Serologic status reflecting active hepatitis B or C infection. Patients with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease. Subjects with uncontrolled intercurrent illness. Known additional malignancies which require systemic treatment. History of autoimmune disease with requirement of immunosuppressive medications (other than low dose steroids) within 6 months.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paolo F. Caimi, MD
Phone
216 445-4635
Email
CAIMIP@ccf.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paolo F. Caimi, MD
Organizational Affiliation
Cleveland Clinic Taussig Cancer Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospitals Seidman Cancer Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leland Metheny, MD
Phone
216-844-0139
Email
Leland.Metheny@uhhospitals.org
Facility Name
Taussig Cancer Institute | Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paolo F Caimi, MD
Email
caimip@ccf.org
First Name & Middle Initial & Last Name & Degree
Kimberly Grundey, MSN RN
Phone
2164424583
Email
mailto:GRUNDEK@ccf.org

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

We'll reach out to this number within 24 hrs